FDA Says To Discontinue Hospira's Morphine Sulfate, Injection, 10 Mg/1 Ml, 4 Mg/1 Ml, 8 Mg/1 Ml- Website
ReutersJul 8, 2025 2:24 PM
July 8 (Reuters) - FDA:
FDA: DISCONTINUES MANUFACTURING OF HOSPIRA'S MORPHINE SULFATE, INJECTION, 10 MG/1 ML, 4 MG/1 ML, 8 MG/1 ML- WEBSITE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Is $4 Trillion Just the Beginning? Citi Backs Nvidia’s AI Dominance
TradingKey - Nvidia (NVDA) made headlines again on Wednesday after its stock surged to 164 during early U.S. trading, pushing its market value past a historic 4 trillion. That makes it the first chip company ever to cross that mark.TradingKey
7 hours ago
NVIDIA and Bitcoin Both Hit Record Highs — How Should Investors Decide Between Them?
On Wednesday, July 9, both NVIDIA (NVDA) and Bitcoin (BTC) reached new all-time highs, sparking debate over which asset offers better long-term potential.TradingKey
16 hours ago
Q2 2025 Earnings Season Preview: The First Test Under Trump’s Tariffs — Could Low Expectations Bring Surprises?
TradingKey - Mid-July will mark the first earnings season since President Donald Trump’s tariff policy took effect, offering investors a glimpse into how American companies are handling the impact of trade tensions. Analysts believe that with low expectations heading into Q2, it may be easier forTradingKey
Wed, Jul 9
Prediction! Federal Reserve Chairman Jerome Powell's Next Move Will Be an Interest Rate Cut
The Federal Reserve must balance the risks of higher inflation with the risks of higher unemployment when making decisions on interest rates.Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »*Stock prices used were..The Motley Fool
Thu, Jun 26
U.S. Big Banks Earnings Q1 2025: Profits Amidst Worries, A Tale of Trump's Mixed Influence?
TradingKey - Against the backdrop of President Donald Trump’s "deregulation" agenda, Wall Street’s major banks have yet to stage a significant rally in early 2025. However, buoyed by high interest rates and policy uncertainty under the Trump administration, the Q1 earnings reports from the six...TradingKey
Fri, Apr 18
Tradingkey
